INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26901, 11155, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26902, 27883, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26903, 27884, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26904, 27885, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26905, 8949, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26906, 11153, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26907, 11155, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26908, 27883, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26909, 27884, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26910, 27885, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26911, 4949, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26912, 27741, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26913, 27742, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26914, 27743, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26915, 4949, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26916, 27741, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26917, 27742, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26918, 27743, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26919, 4949, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26920, 27741, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26921, 27742, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26922, 27743, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26923, 4949, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26924, 27741, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26925, 27742, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26926, 27743, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26927, 4949, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26928, 27741, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26929, 27742, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26930, 27743, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26931, 4949, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26932, 27741, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26933, 27742, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26934, 27743, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26935, 4949, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26936, 27741, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26937, 27742, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26938, 27743, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26939, 4949, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26940, 27741, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26941, 27742, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26942, 27743, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26943, 4949, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26944, 27741, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26945, 27742, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26946, 27743, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26947, 4949, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26948, 27741, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26949, 27742, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26950, 27743, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26951, 4949, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26952, 27741, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26953, 27742, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26954, 27743, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26955, 4949, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26956, 27741, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26957, 27742, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26958, 27743, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26959, 4949, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26960, 27741, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26961, 27742, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26962, 27743, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26963, 0, 'Suvorexant', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26964, 0, 'Suvorexant', 'Kidney Failure, Chronic', 'Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26965, 0, 'Suvorexant', 'Lung Diseases', 'Suvorexant has respiratory depressant effects and should be used with caution in patients with compromised respiratory function.  Suvorexant has not been studied in patients with severe sleep apnea and severe COPD and should not be used in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26966, 0, 'Suvorexant', 'Narcolepsy', 'The use of suvorexant is contraindicated in patient with narcolepsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26967, 0, 'Suvorexant', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26968, 0, 'Suvorexant', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26969, 16929, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26970, 27970, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26971, 30009, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26972, 16929, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26973, 27970, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26974, 30009, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26975, 3617, 'Belladonna', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26976, 3617, 'Belladonna', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26977, 3617, 'Belladonna', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26978, 3617, 'Belladonna', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26979, 3617, 'Belladonna', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26980, 3617, 'Belladonna', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26981, 3617, 'Belladonna', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26982, 3617, 'Belladonna', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26983, 3617, 'Belladonna', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26984, 3617, 'Belladonna', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26985, 3617, 'Belladonna', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26986, 3617, 'Belladonna', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26987, 3617, 'Belladonna', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26988, 3617, 'Belladonna', 'Liver Diseases', 'Atropine-like agents undergo significant hepatic metabolism.  Therapy with atropine-like agents should be administered cautiously to patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26989, 3617, 'Belladonna', 'Renal Insufficiency', 'Atropine-like agents are primarily eliminated by the kidney.  Therapy with atropine-like agents should be administered cautiously to patients with renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26990, 3617, 'Belladonna', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26991, 3617, 'Belladonna', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26992, 3617, 'Belladonna', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26993, 3617, 'Belladonna', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26994, 0, 'Teduglutide', 'Pancreatic Diseases', 'Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical studies with teduglutide.  For identification of the onset or worsening of gallbladder/biliary/pancreatic disease, patients should undergo laboratory assessment of bilirubin, alkaline phosphatase, lipase and amylase within 6 months prior to starting teduglutide, and at least every 6 months while on treatment; or more frequently if needed.  If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder, biliary tract and/or pancreas is recommended; and the need for continued teduglutide treatment should be reassessed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26995, 0, 'Teduglutide', 'Heart Failure', 'Fluid overload and congestive heart failure have been observed in clinical trials with teduglutide.  This was probably related to enhanced fluid absorption associated with the medication.  If fluid overload occurs, parenteral support should be adjusted and treatment should be reassessed, especially in patients with underlying cardiovascular disease.  If significant cardiac deterioration develops while on teduglutide, the need to continue treatment should be reassessed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26996, 0, 'Teduglutide', 'Intestinal Obstruction', 'Intestinal obstruction has been reported in clinical trials with teduglutide.  In patients who develop intestinal or stomal obstruction, treatment with teduglutide should be temporarily discontinued while the patient is clinically managed.  Treatment may be restarted when the obstructive episode resolves, if clinically indicated.  Caution is advised in patients with risk factors for intestinal obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26997, 0, 'Teduglutide', 'Liver Failure', 'Teduglutide pharmacokinetics has not been assessed in patients with severe hepatic impairment.  Caution and monitoring is advised.  Patients with moderate hepatic impairment showed lower Cmax and AUC when compared to healthy matched control subjects after a single subcutaneous dose of teduglutide.  However, no dose adjustment is necessary for patients with mild and moderate liver impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26998, 0, 'Teduglutide', 'Neoplasms', 'Based on the pharmacologic activity and findings in animals, teduglutide has the potential to cause hyperplastic changes including neoplasia.  In patients at increased risk for malignancy, the clinical decision to use teduglutide should be considered only if the benefits outweigh the risks.  In patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic), therapy should be discontinued.  Patients with colorectal polyps, should have these removed within 6 months prior to starting treatment with teduglutide.  In patients with active non- gastrointestinal malignancy, the clinical decision to continue therapy should be made based on risk- benefit considerations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26999, 0, 'Teduglutide', 'Kidney Diseases', 'Teduglutide is primarily cleared by the kidney and caution is advised when using in patients with moderate to severe renal impairment.  The manufacturers recommend to reduced the dose by 50% in patients with moderate and severe renal impairment (creatinine clearance less than 50 mL/min), and end-stage renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27000, 27986, 'Tegaserod', 'Intestinal Obstruction', 'The use of tegaserod is contraindicated in patients with a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.  Stimulation of gastrointestinal motility might be harmful in these conditions.', '3', '', 'DDInter', 0);
